Observational studyJournal of gastrointestinal cancer2025
Diagnostic Utility of Serum CEA and Ca 19.9 as Triage Tools for Predicting Metastatic Disease in Gallbladder Cancer: A Sub-analysis from a Prospective Observational Study.
Observational study in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review.Antibodies (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGallbladder cancer is a highly aggressive malignancy with disproportionate incidence in the Gangetic belt of India. Early diagnosis is critical yet most patients present with advanced-stage disease. Serum tumor markers like CEA and Ca 19.9 are often elevated in gallbladder cancer, but their role in rapidly triaging patients for metastatic disease at presentation has not been prospectively validated in prospective cohort.
methodsThis sub-analysis is part of a larger prospective observational study conducted at a tertiary cancer center in North India. A total of 1500 newly diagnosed, treatment-naïve or incidental gallbladder cancer patients were enrolled between September 2023 and May 2024. Serum CEA and Ca 19.9 levels were measured at baseline. Diagnostic thresholds were derived using the 75th percentile values stratified by obstructive jaundice status. Diagnostic accuracy for predicting metastatic disease was assessed using confusion matrices, ROC curves, and precision-recall analysis.
resultsOf 1500 patients, 1203 (80.2%) presented with metastatic disease. Serum data were available for 1011 patients. Patients with metastatic disease had significantly higher marker levels (CEA: mean 288.4 vs. 22.9 ng/mL; Ca 19.9: 20,917 vs. 2241 U/mL). The model showed high specificity (89.1%) and positive predictive value (92.3%) with moderate AUC (0.74). Sensitivity was limited (40.3%), suggesting strong "rule-in" but weak "rule-out" capability.
conclusionsElevated serum CEA and Ca 19.9 adjusted for jaundice status are strong indicators of metastatic gallbladder cancer at presentation. This real-world percentile-based approach offers a rapid, low-cost diagnostic adjunct for early triage in resource-limited settings. The findings provide context-sensitive thresholds that may aid timely treatment decisions in high-burden regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.